8-K: U.S. Physical Therapy Reports Strong Q3 Results Driven by Volume and Rate Increases

U.S. Physical Therapy saw a 9.3% revenue increase and a 13.4% adjusted EBITDA increase in Q3 2024, driven by strong patient visit volume and net rate growth.

Summary

• U.S. Physical Therapy reported a strong third quarter in 2024, with patient visits increasing by 6% and visits per clinic per day reaching a record high of 30.1.
• The company's net rate per visit rose to $105.65, up from $102.37 in the same quarter last year.
• This combination of increased volume and higher rates drove a 9.3% increase in revenue to $142.2 million for the quarter.
• Adjusted EBITDA for the quarter was up 13.4% compared to the prior year.
• The company closed 32 underperforming clinics to focus on higher-growth areas, bringing the total to 750 locations across 43 states.
• The injury prevention business saw a 30% revenue increase and a 27% operating profit increase compared to Q3 last year.
• Salary-related costs per visit increased by 3.5% to $62.47, but the company held salary costs as a percentage of revenue flat at 57.6%.
• Gross profit, excluding closure costs, increased by 14.4%, and the gross margin for physical therapy improved to 18.9%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, strategic acquisitions, and growth in key business segments. While there are some challenges, the overall tone is optimistic and indicates a well-managed company.

Positives

• Patient visit volume is strong, indicating high demand for services.
• Net rate per visit has increased, contributing to revenue growth.
• The injury prevention business is experiencing significant growth.
• The company is actively managing its portfolio by closing underperforming clinics.
• The recent acquisition of Metro Physical Therapy is expected to be a strong growth engine.
• The company has a strong balance sheet with significant cash reserves.
• The company has a favorable interest rate on its term loan at 4.7%.

Negatives

• Salary-related costs per visit increased by 3.5% year-over-year.
• The company incurred $3.4 million in closure costs related to 32 clinics.
• There is continued rate pressure from Medicare.
• The company is facing wage and other inflation pressures.

Risks

• The company faces risks related to changes in Medicare rules and reimbursement rates.
• There are risks associated with compliance with federal and state laws and regulations.
• The company is exposed to competitive, economic, and reimbursement conditions in its markets.
• The company faces risks related to hiring, training, and retaining qualified employees.
• There are risks associated with the successful integration of acquired businesses.
• The company is exposed to potential legal actions and reputational harm from security breaches.

Future Outlook

The company expects its full-year EBITDA to be within the previously provided range of $80 to $85 million. They anticipate continued growth from recent acquisitions and ongoing operational improvements.

Management Comments

• Chris Reading, CEO, thanked partners and operations support for their focus on care.
• Chris Reading stated that the company is making steady forward progress in key areas.
• Chris Reading mentioned that the company is focused on creating the greatest return on investments.
• Chris Reading emphasized the importance of disciplined deployment of capital.
• Carey Hendrickson, CFO, highlighted the increase in net rate and record high visits per day.
• Carey Hendrickson noted the decrease in contract labor costs and improvement in PT margin.
• Carey Hendrickson stated that the company expects EBITDA to come within the previously provided range of $80 to $85 million.

Industry Context

The company operates in a highly fragmented U.S. outpatient rehab market, with no single company holding more than 10% market share. The market is projected to grow to over $40 billion by 2025, driven by favorable demographics and a shift towards lower-cost, high-quality outpatient providers. USPH is well-positioned to capitalize on this trend through organic growth and strategic acquisitions.

Comparison to Industry Standards

• USPH's patient volume growth of 6% and visits per clinic per day of 30.1 are strong compared to industry averages.
• The company's net rate increase to $105.65 is a positive trend, especially given the Medicare rate reductions.
• USPH's adjusted EBITDA margin of 15.5% is competitive within the industry.
• Select Medical, a large physical therapy operator, has over 1,900 clinics, while USPH has 752, indicating USPH is a significant player but still has room to grow.
• The company's focus on strategic acquisitions and de novo clinic openings aligns with industry trends of consolidation.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and strategic growth initiatives.
• Employees will benefit from the company's focus on growth and development.
• Patients will benefit from the company's commitment to providing high-quality care.
• Partners will benefit from the company's partnership model and growth opportunities.

Next Steps

• The company will focus on integrating the Metro Physical Therapy acquisition.
• The company will continue to optimize its portfolio by managing underperforming clinics.
• The company will continue to pursue strategic acquisitions and de novo clinic openings.
• The company will focus on growing patient volume, improving pricing, and increasing efficiencies.

Key Dates

Keywords

physical therapy, injury prevention, outpatient rehabilitation, healthcare, acquisitions, EBITDA, revenue, Medicare, clinic operations, patient visits